<DOC>
	<DOCNO>NCT01582919</DOCNO>
	<brief_summary>It acknowledge Alzheimer 's disease characterize long period pathophysiological change . Developing new strategy achieve diagnose early possible become major goal therapy aim slow progression disease . While diagnosis currently rely principally clinical neuropsychology , typical diagnostic criterion NINCDS-ADRDA inapplicable early stage disease . The goal project identify early imaging marker Alzheimer 's disease among patient report cognitive difficulty . In order achieve goal , propose longitudinal study elderly population cohort .</brief_summary>
	<brief_title>Neuroimaging Markers Alzheimer Disease : Longitudinal Population Study</brief_title>
	<detailed_description>The AMImage2 project follow AMImage1 MRI-3C consist image study association longitudinal epidemiologic cohort ( AMI 3C ) . The first objective investigate association evolution image marker evolution cognitive performance normal pathological aging . This objective conduct among subject already participate AMImage1 , thereby permit longitudinal study MRI data . An MRI exam also propose 100 subject ( member AMI 3C cohort ) order provide third wave MRI ( longer-term MRI follow-up ) second one participant one MRI exam AMImage project . Our second objective cross-sectional study image parameter subject present sign cognitive decline previous 4 year ( follow-up conduct AMI cohort ) . Finally , additional objective consist comparison two population contrast term cognitive reserve : AMI ( low education level rural area ) 3C ( high level education urban area ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>At least 65 year old Be retire agricultural profession live rural area Gironde ( France ) Lefthanded dementia ( MMSE &lt; 13 ) Having vascular cerebral accident Parkinson disease RMI exclusion criterion [ 18F ] FDG PET SCAN exclusion criterion Poor health condition allow transport neuroimaging service</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>diagnostic</keyword>
	<keyword>biomarkers</keyword>
	<keyword>neuroimaging</keyword>
	<keyword>PET</keyword>
	<keyword>MRI</keyword>
	<keyword>mild cognitive impairment</keyword>
</DOC>